首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Novel 3-methylindoline inhibitors of EZH2: Design,synthesis and SAR
Authors:Amantullah Ansari  Sharad Satalkar  Varshavekumar Patil  Amit S Shete  Simranjeet Kaur  Ashu Gupta  Siddhartha Singh  Mohd Raja  Daniel L Severance  Sebastián Bernales  Sarvajit Chakravarty  David T Hung  Son M Pham  Francisco J Herrera  Roopa Rai
Institution:1. Integral BioSciences Pvt. Ltd., C-64, Hosiery Complex Phase II Extension, Noida, Uttar Pradesh 201306, India;2. Schrodinger, Inc., Portland, OR, USA;3. Medivation, 525 Market Street, 36th Floor, San Francisco, CA 94105, USA
Abstract:EZH2 (enhancer of zeste homologue 2) is the catalytic subunit of the polycomb repressive complex 2 (PRC2) that catalyzes the methylation of lysine 27 of histone H3 (H3K27). Dysregulation of EZH2 activity is associated with several human cancers and therefore EZH2 inhibition has emerged as a promising therapeutic target. Several small molecule EZH2 inhibitors with different chemotypes have been reported in the literature, many of which use a bicyclic heteroaryl core. Herein, we report the design and synthesis of EZH2 inhibitors containing an indoline core. Partial saturation of an indole to an indoline provided lead compounds with nanomolar activity against EZH2, while also improving solubility and oxidative metabolic stability.
Keywords:EZH2  Indoline  Anticancer  Methyltransferases
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号